Sign in
Active, not recruitingNo phase

HPV Self-testing in Transgender Individuals

Key facts

Who runs it
Queen Mary University of London
Where
United Kingdom3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
100 people, planned
Started
29 Feb 2024
Expected to end
29 Nov 2026
Type of study
Interventional, 2 groups
Treatments tested
  • HPV DNA methylation assay
Record updated
19 February 2026

Who can take part

Age
21 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Identify as transgender or non-binary
  • Be between 25 - 65 years of age
  • Be registered with a general practitioner
  • Have an intact cervix
  • Have used testosterone therapy within the last year
  • Be willing, and able to understand and consent to study procedures
  • Identify as transgender or non-binary
  • Be 18 years of age or older
  • Have undergone vaginoplasty by any method at least 1 year ago
  • Be willing, and able to understand and consent to study procedures

Who cannot take part

  • Have a variation of sex characteristics (also known as a disorder of sex development)
  • Have an allergy to any of the ingredients in the oral rinse (Scope)
  • Be diagnosed with, or under investigation for, an inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease). This does not include irritable bowel syndrome - participants with this are eligible to enroll
  • Be a member of a vulnerable population, which includes pregnant people, fetuses, children, prisoners, or anyone unable to independently offer consent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Human papillomavirus (HPV) is a common virus that spreads through skin-to-skin contact. Some HPV types can cause changes in cells that lead to cancer and are known as 'high-risk' HPV (hrHPV). hrHPV is linked to cancers of the cervix (opening of the womb), throat, and anus (exit of the bowel).

Read full original descriptionShow less

It is not known if transgender people (individuals whose gender identity does not align with their sex assigned at birth) are at increased risk of hrHPV or cancers caused by hrHPV compared to cisgender people (individuals whose gender identity does align with their birth sex). There is also little knowledge about HPV in the vagina for transgender women who have surgery to make one.

Transgender men may be at higher risk of cervical cancer than cisgender women because they are less likely to go for screening. This can be because of physical discomfort and emotional distress during screening when a swab is taken directly from the cervix.

The investigators seek to examine how common hrHPV is in transgender people in different parts of the body. In the study, participants will take swabs from the vagina and anus, a urine sample, and use mouthwash. Transgender men will also have an extra swab taken by a clinician as part of routine cervical screening. This is to see if the swab from the vagina is as good as the one from the cervix for finding cells that might lead to cancer. Participants will also take an online survey to measure the acceptability of self-sampling compared to clinician sampling.

This research can inform HPV prevalence and decision-making about HPV screening among transgender people.

The 2 groups in the trial

  • Trans men and non-binary people with a cervixOther group

    Participants will have a clinician-collected cervical screening sample and then collect the following self-samples for research: Vaginal swab, Anal swab, Oral rinse, and Urine sample for the detection of HPV detection.

    Treatment: HPV DNA methylation assay

  • Trans women and non-binary peopleTreatment being tested

    Participants will collect the following self-samples for research in the clinic: Vaginal swab, Anal swab, Oral rinse, and Urine sample for the detection of HPV detection. Participants will collect the following self-samples for research at home: Vaginal swab, Anal swab, and Oral rinse sample for the detection of HPV detection.

    Treatment: HPV DNA methylation assay

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
HPV Methylation Self-testing Pilot in Transgender Individuals
Publications
Record updated
19 February 2026